Circulating Tumor DNA Analysis Associates with Progression- Free Survival ( PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/ R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

被引：1
|
作者：
Arnason, Jon E. [1 ]
Brouwer-Visser, Jurriaan [2 ]
Luminari, Stefano [3 ]
Tucker, David [4 ]
Kim, Tae Min [5 ]
Kim, Won Seog [6 ]
Magnano, Laura [7 ]
Sun, Dylan [2 ]
Cai, Jessica [2 ]
Cygan, Kamil [2 ]
Ambati, Srikanth [2 ]
Mohamed, Hesham [2 ]
Chaudhry, Aafia [2 ]
Jankovic, Vladimir [2 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Azienda Unita Sanit Locale IRCCS, Reggio Emilia, Italy
[4] Royal Cornwall Hosp, Truro, Cornwall, England
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea
[7] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179812
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
  • [22] Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Ambarkhane, Sumeet
    Winderlich, Mark
    Dirnberger-Hertweck, Maren
    Endell, Jan
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [23] Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Rey Bua, Beatriz
    Jimenez Ubieto, A.
    Sanchez Blanco, J. J.
    Abrisqueta, P.
    Gutierrez, A.
    Ramirez Payez, A.
    Gine, E.
    Zeberio Etxetxipia, I.
    Terol, M. J.
    de la Cruz, F.
    Andreu, R.
    Ramirez, M. J.
    de la Fuente, A.
    Viguria, M. C.
    Penarrubia, M. J.
    Grande, C.
    Caballero Barrigon, M. D.
    Martin Garcia-Sancho, A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S381 - S381
  • [24] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
    Diefenbach, Catherine S. Magid
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Lopez-Guillermo, Armando
    Banerjee, Lalita
    McMillan, Andrew
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Seymour, Erlene Kuizon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)-An Interim Analysis
    Schuster, Stephen
    Bishop, Michael R.
    Tam, Constantine
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, Stephen Ronan
    Ho, P. Joy
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Anak, Oezlem
    Pacaud, Lida
    Awasthi, Rakesh
    Tai, Feng
    Salles, Gilles
    Maziarz, Richard T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S373 - S374
  • [26] Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study
    Karmali, Reem
    Landsburg, Daniel J.
    Westin, Jason
    Leonard, John P.
    Kuriakose, Emil T.
    Sumrow, Bradley James
    Carroll, Susheela
    Albert, Katherine
    Akella, Lalith
    Gordon, Leo, I
    BLOOD, 2022, 140 : 12125 - 12126
  • [27] A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Torka, Pallawi
    Bhat, Seema
    Lee, Kelvin P.
    Hutson, Alan
    Nichols, Jenna
    Kader, Angela
    Mavis, Cory
    Block, AnneMarie W.
    Sait, Sheila N. J.
    Baysal, Bora E.
    Habib, Fadi
    Neppalli, Vishala T.
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD, 2017, 130
  • [28] LENALIDOMIDE MONOTHERAPY IS CLINICALLY ACTIVE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POOLED ANALYSIS OF DATA FROM 2 PHASE II STUDIES (NHL-002/003)
    Czuczman, M.
    Vose, J.
    Zinzani, P. L.
    Reeder, C.
    Buckstein, R.
    Haioun, C.
    Bouabdallah, R.
    Polikoff, J.
    Ervin-Haynes, A.
    Witzig, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 239 - 239
  • [29] Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Nowakowski, Grzegorz S.
    Yoon, Dok Hyun
    Joffe, Erel
    Zinzani, Pier Luigi
    Sabatelli, Lorenzo
    Waltl, Eva E.
    Alvero, Carmelita G.
    Hess, Georg
    Riedell, Peter A.
    Kim, Kibum
    Brixner, Diana
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
    Sanjal H. Desai
    Betsy LaPlant
    William R. Macon
    Rebecca L. King
    Yucai Wang
    David J. Inwards
    Ivana Micallef
    Patrick B. Johnston
    Luis F. Porrata
    Stephen M. Ansell
    Thomas M. Habermann
    Thomas E. Witzig
    Grzegorz S. Nowakowski
    Blood Cancer Journal, 11
12345